Quantcast

Latest Jazz Pharmaceuticals plc Stories

2014-02-25 16:29:54

Chief Financial Officer Kathryn Falberg to Step Down; Matthew Young Appointed CFO DUBLIN, Feb. 25, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Kathryn Falberg, executive vice president and chief financial officer (CFO), has resigned from the company, effective March 9, 2014, to pursue other interests. Ms. Falberg will serve as a consultant to Jazz Pharmaceuticals during a transition period. Matthew Young, senior vice president of corporate...

2014-02-25 16:29:42

Company Reports Total Revenues of $872 Million in 2013 Driven by Strong Sales of Xyrem and Erwinaze DUBLIN, Feb. 25, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and the fourth quarter ended December 31, 2013 and provided financial guidance for 2014. "2013 was an outstanding year as we delivered strong top-line growth, generated significant cash flow and executed on our corporate development strategy," said Bruce Cozadd,...

2014-02-21 08:25:31

Approximately 98 percent of outstanding Gentium ordinary shares and American Depositary Shares tendered DUBLIN, Feb. 21, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the subsequent offering period of the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares ("ADSs") of Gentium S.p.A. (Nasdaq: GENT) for $57.00 per share and per ADS (without duplication for ordinary...

2014-02-11 16:25:48

DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2013 fourth quarter and full year financial results on Tuesday, February 25, 2014, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST/9:30 p.m. GMT to provide a business and financial update and discuss fourth quarter and full year 2013 financial results and provide...

2014-02-11 16:25:38

First liquid formulation clozapine for treatment-resistant schizophrenia DUBLIN, Feb. 11, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced U.S. commercial availability of Versacloz(TM) (clozapine, USP) oral suspension, the first and only oral suspension clozapine for severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. "We are pleased to offer patients with...

2014-02-10 08:26:53

DUBLIN, Feb. 10, 2014 /PRNewswire/ --Jazz Pharmaceuticals (Nasdaq: JAZZ) today announced that it has commenced construction of a manufacturing and development facility to be located on a 17-acre site in Monksland, County Roscommon, approximately 75 miles east of the company's Dublin headquarters. This is the first manufacturing facility to be built by Jazz Pharmaceuticals. "Today marks a milestone for Jazz Pharmaceuticals as we break ground in Ireland and begin, for the first...

2014-01-23 04:21:14

Approximately 79 percent of outstanding Gentium ordinary shares and American Depositary Shares tendered DUBLIN, Jan. 23, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the initial offering period in the tender offer made by a subsidiary of Jazz Pharmaceuticals to purchase all outstanding ordinary shares and American Depositary Shares ("ADSs") of Gentium S.p.A. (Nasdaq: GENT) for $57.00 per share and per ADS (without duplication for ordinary shares...

2014-01-13 08:28:21

Terms include $125 million upfront payment in cash plus a potential of up to $272 million in milestone payments DUBLIN, Jan. 13, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Aerial BioPharma, LLC (Aerial) today announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Under the...

2014-01-09 08:23:54

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, January 9, 2014 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), AmerisourceBergen Corporation (NYSE: ABC), and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Today's readers may access these reports free of charge -...

2014-01-06 16:27:51

DUBLIN, Jan. 6, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Bruce C. Cozadd, chairman and chief executive officer, will provide an overview of the company and provide a business and financial update at the conference on Monday, January 13, 2014 at 10:00 a.m. PST / 6:00 p.m. GMT. A live audio webcast of the...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related